This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gupta, E. Articles by Ratain, M. J. Search for Related Content PubMed PubMed Citation Articles by Gupta, E. Articles by Ratain, M. J.

Pharmacokinetic Modulation of Irinotecan and Metabolites by Cyclosporin A¹

Section of Hematology/Oncology, Department of Medicine [E. G., A. R. S., X. W., M. J. R.], Committee on Clinical Pharmacology [M. J. R.] and Cancer Research Center [A. R. S., M. J. R.], The University of Chicago, Chicago, Illinois 60637

The focus of this investigation was to modulate the pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G, by possibly reducing biliary excretion, which in turn could lower irinotecan toxicity. We determined the effect of a known cholestatic agent, cyclosporin A (CsA), which is transported across the bile canalicular membrane by P-glycoprotein, on the biliary excretion of irinotecan and its metabolites. Wistar rats were pretreated with 60 mg/kg CsA 5 min before an i.v. dose of irinotecan at dose levels of 6, 10, and 20 mg/kg. The control groups received irinotecan only. CsA pretreatment resulted in an average increase of 339, 361, and 192% in the area under the plasma concentration-time curve of irinotecan, SN-38, and SN-38G, respectively. Analysis of clearance (CL) of irinotecan indicated a 55 and 81% reduction in the average renal and nonrenal CLs, respectively, in the pretreated groups. The nonrenal CL, which is the primary component of irinotecan CL, includes protein and tissue binding as well as the metabolic and biliary CL of irinotecan. There was no change in the volume of distribution at steady state (indicative of unchanged binding) and in the metabolic conversion of irinotecan to SN-38 due to pretreatment. Therefore, the significant reduction in the systemic CL of irinotecan due to CsA pretreatment was primarily due to lowered biliary excretion. Studies using a photoaffinity analogue of verapamil, [¹²⁵I]NAS-VP, and membrane vesicles from the multidrug-resistant cell line, MCF-7/Adr, revealed that irinotecan and metabolites had moderate interaction with P-glycoprotein. Further studies are required to determine the mechanism of the inhibitory effect of CsA on the biliary excretion of irinotecan and its metabolites.

¹ This work was supported in part by Grants DHP-100 and CA 56078 from the American Cancer Society and the National Cancer Institute, respectively.

² To whom requests for reprints should be addressed, at The University of Chicago Medical Center, MC2115, 5841 South Maryland Avenue, Chicago, IL 60637. Phone: (312) 702-1815; Fax: (312) 702-3163; E-mail: mcis@bsd.uchicago.edu.

Received 7/11/95. Accepted 1/16/96.

This article has been cited by other articles:

				M. J. Ratain From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin. Cancer Res., March 15, 2006; 12(6): 1658 - 1660. [Full Text] [PDF]

				W. P. Yong, J. Ramirez, F. Innocenti, and M. J. Ratain Effects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes Clin. Cancer Res., September 15, 2005; 11(18): 6699 - 6704. [Abstract] [Full Text] [PDF]

				T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS Drug Metab. Dispos., March 1, 2005; 33(3): 434 - 439. [Abstract] [Full Text] [PDF]

				M. A Rudek, K. S Bauer Jr, R. M Lush III, S. F Stinson, A. M Senderowicz, D. J Headlee, S. G Arbuck, M. C Cox, A. J Murgo, E. A Sausville, et al. Clinical Pharmacology of Flavopiridol Following a 72-Hour Continuous Infusion Ann. Pharmacother., October 1, 2003; 37(10): 1369 - 1374. [Abstract] [Full Text] [PDF]

				J. D. Chester, S. P. Joel, S. L. Cheeseman, G. D. Hall, M. S. Braun, J. Perry, T. Davis, C. J. Button, and M. T. Seymour Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer J. Clin. Oncol., March 15, 2003; 21(6): 1125 - 1132. [Abstract] [Full Text] [PDF]

				Y. Xu and M. A. Villalona-Calero Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann. Onc., December 1, 2002; 13(12): 1841 - 1851. [Abstract] [Full Text] [PDF]

				D. F.S. Kehrer, R. H.J. Mathijssen, J. Verweij, P. de Bruijn, and A. Sparreboom Modulation of Irinotecan Metabolism by Ketoconazole J. Clin. Oncol., July 15, 2002; 20(14): 3122 - 3129. [Abstract] [Full Text] [PDF]

				F. R. Luo, P. V. Paranjpe, A. Guo, E. Rubin, and P. Sinko Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1 Drug Metab. Dispos., July 1, 2002; 30(7): 763 - 770. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				R. H. J. Mathijssen, R. J. van Alphen, J. Verweij, W. J. Loos, K. Nooter, G. Stoter, and A. Sparreboom Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11) Clin. Cancer Res., August 1, 2001; 7(8): 2182 - 2194. [Abstract] [Full Text] [PDF]

				M. L. Rothenberg Irinotecan (CPT-11): Recent Developments and Future Directions-Colorectal Cancer and Beyond Oncologist, February 1, 2001; 6(1): 66 - 80. [Abstract] [Full Text]

				M. J. Ratain Insights into the Pharmacokinetics and Pharmacodynamics of Irinotecan Clin. Cancer Res., September 1, 2000; 6(9): 3393 - 3394. [Abstract] [Full Text]

				F. Innocenti, W. M. Stadler, L. Iyer, J. Ramírez, E. E. Vokes, and M. J. Ratain Flavopiridol Metabolism in Cancer Patients Is Associated with the Occurrence of Diarrhea Clin. Cancer Res., September 1, 2000; 6(9): 3400 - 3405. [Abstract] [Full Text]

				X.-Y. Chu, Y. Kato, and Y. Sugiyama Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats Drug Metab. Dispos., April 1, 1999; 27(4): 440 - 441. [Abstract] [Full Text]

				P. Klein and F. M. Muggia Cytoprotection: Shelter from the Storm Oncologist, April 1, 1999; 4(2): 112 - 121. [Full Text]

				S. Akhteruzzaman, Y. Kato, A. Hisaka, and Y. Sugiyama Primary Active Transport of Peptidic Endothelin Antagonists by Rat Hepatic Canalicular Membrane J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 575 - 581. [Abstract] [Full Text]